Rising Prevalence Of Gastrointestinal Disorders To Drive Market Growth: Strengthening the Growth Trajectory of the Viral Gastroenteritis Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Viral Gastroenteritis Market Through 2025?
The market size of viral gastroenteritis has enjoyed a consistent growth over the past few years. It's predicted to rise from $6.75 billion in 2024 to $7.08 billion in 2025, marking a compound annual growth rate (CAGR) of 5.0%. The factors that contributed to growth in the historic period include the widespread occurrence of viral infections, worldwide sanitation habits, progress in diagnostic tools, international travel and tourism, as well as climatic and environmental elements.

What's the Projected Size of the Global Viral Gastroenteritis Market by 2029?
We expect the market size of viral gastroenteritis to experience significant expansion in the near future, with projections suggesting it will reach a worth of $8.73 billion by 2029, at a compound annual growth rate (CAGR) of 5.4%. The predicted upswing during this period can be linked to elements such as heightened global health readiness, the effects of climate change, the implementation of a one health approach, the use of epidemiological surveillance systems, the role of education, and public consciousness. Looking ahead, anticipated trends in this period encompass vaccine development, cutting-edge diagnostics, the application of telemedicine in diagnosis, joint research efforts, the utilization of personalized medicine tactics, and the incorporation of digital health solutions.

View the full report here:
https://www.thebusinessresearchcompany.com/report/viral-gastroenteritis-global-market-report

Top Growth Drivers in the Viral Gastroenteritis Industry: What's Accelerating the Market?
The escalating occurrence of gastrointestinal disorders is projected to drive the expansion of the viral gastroenteritis market in the future. Diseases that happen within or on the gastrointestinal tract are known as gastrointestinal (GI) disorders. The provision of accurate and suitable medication is assisted by viral gastroenteritis drugs and diagnosis treatments for those afflicted with the disease. For example, the Impact of IBD Report 2023, published by IBD Clinical and Research Centre, a Canada-centered organization dedicated to enhancing the lives of patients with Crohn's disease and ulcerative colitis, claimed in September 2023 that over 320,000 individuals in Canada were suffering from inflammatory bowel disease (IBD), reflecting a prevalence of 825 per 100,000 in 2023. With an anticipated annual increase of 2.44% in prevalence, it is estimated that by 2035, 1.1% of the population or 470,000 Canadians, will be living with IBD. Consequently, the escalating occurrence of gastrointestinal disorders is fueling the expansion of the viral gastroenteritis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12127&type=smp

What Trends Will Shape the Viral Gastroenteritis Market Through 2029 and Beyond?
Product innovation is becoming an increasingly dominant trend in the viral gastroenteritis market. Many of the major market players are prioritizing the development of new offerings to solidify their market standing. For example, GlaxoSmithKline PLC, a biopharmaceutical corporation based in the UK, got the nod from the US Food and Drug Administration (FDA) in November 2022 for its oral-dosing instrument-only (liquid formulation) version of ROTARIX, which is used to prevent rotavirus gastroenteritis in infants. The new formulation allows a more straightforward application process for healthcare professionals, removing the necessity to mix the vaccine dose at the time of administration. The endorsement was backed by global clinical trial findings that showed its safety and tolerability against the lyophilized formulation and the non-inferiority of its immunogenicity.

What Are the Main Segments in the Viral Gastroenteritis Market?
The viral gastroenteritis market covered in this report is segmented -

1) By Drugs: Antibiotics, Antacids, Laxatives, Antimotility Agents, Others Drugs
2) By Diagnosis: Physical Examination, Rapid Stool Test
3) By Indication: Watery Diarrhea, Abdominal Cramps, Pain, Other Indications
4) By Type Of Virus: Norovirus, Rotavirus, Astrovirus, Enteric Adenovirus
5) By End User: Hospitals, Clinics, Pharmaceutical Companies, Diagnostic Centers, Ambulatory Care Centers, Others End Users

Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Penicillins, Macrolides, Cephalosporins
2) By Antacids: Proton Pump Inhibitors (PPIs), Histamine-2 Receptor Antagonists (H2 Blockers), Magnesium-Based Antacids, Calcium-Based Antacids, Sodium Bicarbonate
3) By Laxatives: Bulk-Forming Laxatives, Osmotic Laxatives, Stimulant Laxatives, Stool Softeners
4) By Antimotility Agents: Loperamide, Diphenoxylate
5) By Other Drugs: Oral Rehydration Salts (Ors), Zinc Supplements, Antiemetics

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12127&type=smp

Which Top Companies are Driving Growth in the Viral Gastroenteritis Market?
Major companies operating in the viral gastroenteritis market include Pfizer Inc., Abbvie Inc., Sanofi S.A., Abbott Laboratories, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, C.H. Boehringer Sohn AG & Co. KG, Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Alexion Pharmaceuticals Inc., Horizon Therapeutics Plc, Dr. Reddy's Laboratories Ltd., BioMarin Pharmaceutical Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd, Ironwood Pharmaceuticals Inc, ANI Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Allergan plc, Haustus Biotech Private Limited, Gracia Lifesciences India Private Limited

Which Regions Will Dominate the Viral Gastroenteritis Market Through 2029?
North America was the largest region in the viral gastroenteritis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral gastroenteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12127

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.